🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Rehabilitation of People With Post-tuberculosis Lung Disease

RecruitingNAAges 18 Years - anyAllCentro Universitário Augusto Motta
NCT06127641 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Tuberculosis (TB) can leave numerous sequelae, where survivors experience a transition from an acute illness to living with a multifaceted chronic illness. Post-TB lung disease (PD-PTB) encompasses lung diseases and pathologies that occur after one or more episodes of TB, which can affect the patient's lung health and cause disabling symptoms that strongly affect their long-term health. In 2020, it was estimated that there were 155 million TB survivors still alive worldwide, with a large proportion of them carrying functional sequelae with profound socioeconomic repercussions. Thus, the aim of this study is to evaluate the effect of pulmonary rehabilitation (PR) on functionality and health-related quality of life (HRQoL) of people with PD-PTB and to build a PD-PTB severity scoring system based on the data. of pre-RP individuals using artificial intelligence technique.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with post-tuberculosis lung disease, clinically stable and able to perform \>80% of training sessions. Exclusion Criteria: * Presence of comorbidities not related to PD-PTB. * Patients with inability to perform TGlittre. * Patients who have cognitive changes that impair their inclusion in the study. * Treatment abandonment during the application of the PR protocol. * Uncontrolled hypertension or use of psychotropic medications. * Any significant limitations due to osteoarthropathy. * Having had any orthopedic surgery in the previous year.
💊

What it tests

  • Standard care plus pulmonary rehabilitation
  • Standard Care
📍

Where

2 sites
Agnaldo José Lopes
Rio de Janeiro, Brazil
Centro Universitario Augusto Motta
Rio de Janeiro, Brazil
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy